Literature DB >> 8641317

Legal opioid consumption in Denmark 1981-1993.

T Groth Clausen1, J Eriksen, F M Borgbjerg.   

Abstract

According to the World Health Organisation, a country's morphine consumption is an important indicator of progress in cancer pain relief. Due to its very high opioid consumption, Denmark is often pointed out as a country worthy of imitation. The aim of the present study was to analyse Danish opioid consumption in order to elucidate the usage pattern and to identify the consumers. Total opioid consumption increased 353% from 1981 to 1993, exceeding 1.45 million defined daily doses per million inhabitants in 1993. Morphine accounted for 39%, methadone 22%, ketobemidone 21% and buprenorphine for 14% of the consumption use. The consumption of long acting opioids (sustained release morphine, methadone, buprenorphine) and short acting opioids (others) increased by 1427% and 105%, respectively. Analysis of a sample of 1854 prescriptions for opioids revealed that less than 10% of the prescriptions were issued for cancer pain conditions. It is concluded: that if other countries consider Denmark as worthy of imitation in opioid treatment for cancer pain, attention should be paid to the pattern of the Danish opioid consumption, which is outstanding with respect to quantity but the quality may be questionable.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8641317     DOI: 10.1007/bf00194945

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

Review 1.  Cancer pain relief and palliative care. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1990

Review 2.  Treatment principles for the use of opioids in pain of nonmalignant origin.

Authors:  S A Schug; A F Merry; R H Acland
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

3.  Analgesic treatment in acute myocardial infarction. A double-blind comparison of ketobemidone + the spasmolytic A29 (Ketogan) and morphine.

Authors:  T Wolff; S Leward; A Hagman; M Andersson; L Larsson; K Elgen
Journal:  Acta Med Scand       Date:  1988

4.  Clinical pharmacokinetics and oral bioavailability of ketobemidone.

Authors:  U Bondesson; S Arnér; P Anderson; L O Boréus; P Hartvig
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

  4 in total
  3 in total

Review 1.  Opioids in chronic noncancer pain: more faces from the crowd.

Authors:  C Peter N Watson
Journal:  Pain Res Manag       Date:  2012 Jul-Aug       Impact factor: 3.037

2.  Using a morphine equivalence metric to quantify opioid consumption: examining the capacity to provide effective treatment of debilitating pain at the global, regional, and country levels.

Authors:  Aaron M Gilson; Martha A Maurer; Karen M Ryan; Paul J Rathouz; James F Cleary
Journal:  J Pain Symptom Manage       Date:  2012-09-24       Impact factor: 3.612

3.  Trends of Opioid Utilisation in Denmark: A Nationwide Study.

Authors:  Søren Kabell Nissen; Anton Pottegård; Jesper Ryg
Journal:  Drugs Real World Outcomes       Date:  2019-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.